| E-Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Health and Fitness > Back Pain > Osteoporosis And The Loss Of Bone Density |
|
E-Articles - Osteoporosis And The Loss Of Bone Density
Osteoporosis is a health condition suffered by many today of which the hallmark is the loss of the normal bone density According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product and the subsequent fragility of the skeletal bones. Because of the loss of or the reduction in the bone density in the ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in original skeletal structure, the skeletal bones lose their strength putting the osteoporotic bones at a much higher ris lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. k for fracture. But osteoporosis leads to bones that look like a sponge. These bones are abnormally porous and begin i here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe the worst-case situations to look a lot like Swiss cheese. Osteoporosis weakens the entire skeletal system and puts th d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro e sufferer at great risk for bone fracture. The morbidity associated with bone fractures in the aging population is qu ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc te high. The anecdotal stories recalled time and time again of senior citizens failing to ever really recover from a b easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi one fracture seem to point as clear evidence of the high morbidity of skeletal fractures. With osteoporosis bone fract nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically re easily. In fact a minor fall or simple injury that in the majority of the population might only cause a bump or bru and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ise, but in a person suffering from osteoporosis it can lead to a severe fracture. The wrist, hips, and spine are the ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ost common locations of osteoporosis-related bone fractures; however, osteoporosis-related fractures can also develop i ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a almost any skeletal bone area. Normal bone is composed of the collagen, calcium, and protein. But with osteoporosis t dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod hese are no longer well represented. Fractures associated with osteoporosis can be in the form of a collapse such as i cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin the case with a compression fracture of the vertebrae in the spine or it can be a fracture in the form of a crack such tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen as when you see a complete hip fracture. While treatment options are more readily available, the key to osteoporosis t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel s prevention. Once a break occurs the ramifications of that will be with you for life. It seems currently that women h ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ave a higher incidence of osteoporosis. This is thought to be related to the many hormonal changes experienced by a wom y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products n during her lifetime. Osteoporosis is a preventable disease. The morbidity and mortality associated with osteoporosi . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de s is something that must be taken seriously. Make sure that you see your health care provider on a yearly basis in ord elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip r to have a current assessment about the status of your bone density particularly if you are a woman over the age of 35 tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Many Advantages Far Outweigh Few Disadvantages of Stored Value Cards Personal Loans - Anyone In Need Of Cash Can Find A Suitable Deal If You Can See it, You Can Get it!
|